NORTRIPTYLINE CAPSULE

देश: कनाडा

भाषा: अंग्रेज़ी

स्रोत: Health Canada

सक्रिय संघटक:

NORTRIPTYLINE (NORTRIPTYLINE HYDROCHLORIDE)

थमां उपलब्ध:

APOTEX INC

ए.टी.सी कोड:

N06AA10

INN (इंटरनेशनल नाम):

NORTRIPTYLINE

डोज़:

10MG

फार्मास्यूटिकल फॉर्म:

CAPSULE

रचना:

NORTRIPTYLINE (NORTRIPTYLINE HYDROCHLORIDE) 10MG

प्रशासन का मार्ग:

ORAL

पैकेज में यूनिट:

100

प्रिस्क्रिप्शन प्रकार:

Prescription

चिकित्सीय क्षेत्र:

TRICYCLICS AND OTHER NOREPINEPHRINE-REUPTAKE INHIBITORS

उत्पाद समीक्षा:

Active ingredient group (AIG) number: 0102630002; AHFS:

प्राधिकरण का दर्जा:

APPROVED

प्राधिकरण की तारीख:

2021-04-06

उत्पाद विशेषताएं

_NORTRIPTYLINE (_
_Nortriptyline Hydrochloride Capsules_
_) _
_ _
_ _
_ _
_ _
_ Page 1 of 33_
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
NORTRIPTYLINE
Nortriptyline Hydrochloride Capsules
Capsules, 10 mg and 25 mg, Oral
USP
Antidepressant
APOTEX INC.
150 Signet Drive
Toronto, Ontario
M9L 1T9
Date of Initial Authorization:
APR 01, 2021
Date of Revision:
APRIL 5, 2023
Submission Control Number: 269184
_NORTRIPTYLINE (_
_Nortriptyline Hydrochloride Capsules_
_) _
_ _
_ _
_ _
_ _
_ Page 2 of 33_
_ _
RECENT MAJOR LABEL CHANGES
N/A
N/A
TABLE OF CONTENTS
_ _
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED._ _
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATION
.................................................................................................................
4
1.1
PEDIATRICS
................................................................................................................
4
1.2
GERIATRICS
.................................................................................................................
4
2
CONTRAINDICATIONS
..................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS
.....................................................................
4
4
DOSAGE AND ADMINISTRATION
..................................................................................
5
4.1
DOSING CONSIDERATIONS
............................................................................................
5
4.2
RECOMMENDED DOSE AND DOSAGE ADJUSTMENT
....................................................... 5
4.4
ADMINISTRATION
..............................